Trends and Finance: Page 6

Invitae sells reproductive health assets to Natera

By LabPulse.com staff writers

Invitae on Monday has completed the sale of some of its reproductive health assets, including carrier screening and noninvasive prenatal screening, to Natera.

January 22, 2024

Accent Therapeutics raises $75M in series C funding round

By LabPulse.com staff writers

Biopharmaceutical company Accent Therapeutics has raised $75 million in a series C financing round, with the aim of using the funds to advance two of its precision oncology candidates to clinical trials.

January 23, 2024

Ravgen wins $57M in patent infringement suit against Natera

By LabPulse.com staff writers

A jury in Austin, TX, awarded biotech firm Ravgen $57 million in damages in its patent infringement lawsuit against Natera.

January 18, 2024

Elizabeth Holmes gets 90 years exclusion

By LabPulse.com staff writers

HHS-OIG adds extended federal healthcare program exclusion onto Theranos executive's punishment.

January 19, 2024

Optithera, ELNA Medical Group, Génome Québec partner on diabetes complications risk assessment test

By LabPulse.com staff writers

Optithera, ELNA Medical Group, and Génome Québec have signed an agreement to further develop and distribute a genomic test to predict the risk of complications in patients with type 2 diabetes.

January 18, 2024

Genevant Sciences forges $114M deal with Tome Biosciences on liver disease gene therapy

By LabPulse.com staff writers

Biotech firm Genevant Sciences will collaborate with biotech startup Tome Biosciences on an in vivo gene editing treatment for a rare liver disorder.

January 16, 2024

Geneoscopy requests review of Exact Sciences patent, dismissal of lawsuit

By LabPulse.com staff writers

In the latest development in the patent infringement dispute between the two companies, Geneoscopy has petitioned the U.S. Patent and Trademark Office for inter partes review, challenging the patent in contention held by Exact Sciences.

January 12, 2024

Myrobalan Therapeutics completes $24M series A financing round

By LabPulse.com staff writers

Biotech company Myrobalan Therapeutics completed a $24 million series A financing round Wednesday.

January 11, 2024

COVID-19 fraud conviction overturned by federal judge

By LabPulse.com staff writers

A federal judge has overturned a jury verdict convicting a Maryland doctor of five counts of COVID-19 testing fraud.

January 9, 2024

Steward offloads outreach laboratory services business

By LabPulse.com staff writers

Quest Diagnostics has acquired select assets of outreach laboratory services in Pennsylvania and Ohio from Steward Health Care System, a large, private, and fully-integrated for-profit system based in Dallas.

January 9, 2024

NanoString to cut 50 jobs; receives Nasdaq delisting notice

By LabPulse.com staff writers

In a filing with the SEC, NanoString announced plans to cut approximately 50 jobs, about 9% of its global workforce, as part of its plan to “decrease its costs and create a more streamlined organization to support its business.”

January 8, 2024

Tome Biosciences acquires Replace Therapeutics in $65M deal

By LabPulse.com staff writers

Less than a month after Tome Biosciences emerged with $213 million in funding, the gene editing company will acquire Replace Therapeutics for $65 million in upfront and near-term milestones, with a total deal value of up to $185 million.

January 5, 2024

Previous Page

Page 6 of 134

Next Page